Primary CD has two main clinical forms. The first is characterized by abnormal posture of the head and neck, limitation of head movements, and hypertrophy of overactive muscles, but no involuntary head movements. The abnormal posture can be purely rotational (torticollis), head tilt (laterocollis), head retroflexion (retrocollis), or anteflexion (antecollis), or a combination.
Torticollis is the most common among single deviations, while torticollis plus laterocollis is the most common of the combined forms. The second form is characterized by the features of the first type plus involuntary head jerks (myoclonic dystonia). The head jerks are often exaggerated when the patient attempts to move the head toward the direction of movement limitation, and are sometimes seen exclusively at the end of the attempted rotation. In some patients, head movements are oscillatory (dystonic tremor) and difficult to differentiate from the cervical form of essential tremor. Remission occurs in 10-20% of patients, but is generally transient and usually does not last beyond one year. 5, 6 Approximately 10% of patients disclose a history of CD in first-degree relatives, and 26-52% describe tremor or dystonia in family members. 6 CD is distinct from other forms of late-onset dystonia because of pain, which is often described as 'aching' or 'pulling' and occurs in 70-75% of patients. 7, 8 In one study the following distribution was reported: neck, 100%; shoulder, 73%; back, 46%; and arm, 15%. The maximum pain is usually felt in the muscles ipsilateral to the side of the chin deviation. Patients learn to perform sensory tricks (geste antagoniste) to improve head posture and decrease neck pain. The most common maneuver is touching the chin on the side of ipsilateral head rotation or tilt. However, pressing the head back against a high chair and holding the occipital region between interlocked fingers may also work. Sensory tricks usually lose some of their effectiveness with the passage of time.
Differential diagnosis of late-onset CD includes a number of secondary causes.
Dystonic posture of the neck may arise from cervical spine disease or disorders of the cervico-cranial junction. CD can occur after head or neck injury, and dystonic posture of the neck may be seen during the course of a number of neurodegenerative disorders such as Parkinson's disease, Parkinson plus syndromes, and Wilson's disease. In the DYT7 form of genetic dystonia the pattern of dystonia is focal and often affects the cervical region. In some patients with DYT1 dystonia, CD may be the most prominent feature. In younger patients, the work-up should include brain magnetic resonance imaging (MRI), metabolic screening, and-in some patients-genetic testing.
In older patients, when there is a suspicion of cervical spine disease one should obtain MRI of the cervical spine and the cervico-cranial junction.
Koukouni et al. 10 reported clinical and genetic characteristics of 76 patients with CD with age at onset below 28 years (mean 21 years). The male-tofemale ratio was 1.24:1, and there was a family history of dystonia or tremor in 26%. Neck trauma or surgery was present in 17% of the patients. Onethird developed dystonia in the contiguous parts of the body. Another one-third experienced partial remission, but dystonia relapsed within five years. The DYT1 gene mutation was negative in all 15 patients who were tested for it. This young-onset CD seems to be distinct from the more common late-onset form of CD in terms of male predominance, higher incidence of family involvement, and more transient remissions.
Primary CD is probably a genetic disorder, but the precise genetic alteration needs to be elucidated. In one German kindred with DYT7 mutation, CD was the prominent dystonic feature. 11 In a recent study, the investigators showed that the presence of the D216H variant of the DYT1 gene in the absence of the DYT1 mutation increases the risk for developing CD even in patients without a family history of CD.
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Medical Treatment
The most commonly used pharmacological agents for the treatment of (CGRP), and glutamate, [15] [16] [17] anti-inflammatory effect, 17 and suppression of muscle spindle discharge resulting in reduced excitation of gamma and alpha motor neurons. 18 It has been shown that pain improves sooner and independently from neck posture in CD after BoNT treatment. 19, 20 Currently, three formulations of BoNT-A are commercially available for BoNT-A (Dysport), and three with BoNT-B (Myobloc). All six studies depicted superiority of BoNTs to placebo in terms of efficacy and safety. [22] [23] [24] [25] [26] [27] The trihexyphenidyl study 28 was conducted with BoNT-A (Dysport), which was proved to be more efficacious than tirhexyphenidyl in improving motor disability and movements while producing fewer adverse effects. The AAN subcommittee concluded that BoNTs are established as safe and effective for the treatment of CD, and that BoNT injections should be offered as a treatment option to patients with CD (level A). Improvement of pain and abnormal head and neck postures in these studies ranged from 60 to 95%.
Comella's recent review additionally analyzed four double-blind studies that compared two BoNTs with each other in terms of efficacy, tolerability, and side effects. 29 Of these four studies, two compared BoNT-A (Botox) with
BoNT-A (Dysport), 30, 31 one compared Botox with BoNT-A (Xeomin), 32 and one compared Botox with BoNT-B (Myobloc). 33 One of the two Dysport/Botox studies in CD showed comparable efficacy and side effects when the investigators used the ratio of three Dysport units to one Botox unit. 30 In another Dysport/Botox study using two ratios of 3:1 and 4:1, patients who received Dysport had more improvement in terms of pain and neck posture, but showed more side effects. 31 The Xeomin/Botox study 32 showed no difference between the two in terms of improvement of total TWSTRS score and TWSTRS pain score. Both BoNTs displayed the same frequency of side effects in this study. A ratio of 1:1 was used for this study.
The comparison studies between Botox and Myobloc are more relevant to the practice of BoNT therapy in the US. In a blinded study, Comella et al. 33 compared improvement of TWSTRS score at four weeks between 74 and 65 CD patients who received Botox and Myobloc, respectively. There was no significant difference between the two groups with regard to TWSTRS score. Rates of dysphagia and dry mouth were significantly higher in the Myobloc group (48 versus 19% and 80 versus 41%, respectively). The higher incidence of these adverse effects may be due to the structured interview adverse effect assessment utilized in the study, and also to the fact that all patients were naïve to Myobloc. The duration of Botox action was marginally longer than that of Myobloc (14 versus 12.1 weeks). A recent European double-blind, multicenter study 34 compared Botox with Myobloc in naïve patients with CD (55 Botox, 56 Myobloc). The study showed no significant difference between the two in terms of TWSTRS total score or subscores (pain, severity, or disability) at four weeks, or in terms of duration of action. There was also no statistically significant difference between the two in terms of dysphagia, pain at the site of injection, and moderate or severe dryness of the mouth. Mild dryness of the mouth was more common in the Myobloc group.
Emergence of unresponsiveness after chronic use of BoNTs is a treatment obstacle. A comprehensive review of CD in 1998 cited a figure of 5-10% for unresponsiveness. 6 Multiple factors could contribute to the clinical unresponsiveness, including the development of neutralizing antibodies.
Although unresponsiveness often relates to the development of neutralizing antibodies, some patients continue to respond despite having them. The exact correlation between neutralizing antibodies and the clinical unresponsiveness is not well established or understood at this time. Administration of large doses of BoNTs in one session (>300 units for Botox) and short intervals between the injections (<3 months) enhances antibody formation. In practice, unresponsiveness is rare with the new formulation of BoNT-A (Botox, introduced after 1997). Jankovic et al. found no neutralizing antibodies in a study of 119 patients treated with the new formulation, whereas 9.5% of the patients treated with the old formulation had the antibodies. 35 Brin et al. 36 studied the incidence of neutralizing antibodies in 326 patients with CD followed for an average period of 2.5 years with repeat Botox treatments (mean nine treatments). Four patients (1.2%) developed neutralizing antibodies and three of 251 patients (1.1%) who completed the study became unresponsive during treatment. These figures are considerably lower than the incidence of 5-10% cited in the earlier reports. 6 The lower figures are probably due to the lower protein content of the new Botox preparation (5 versus 25ng) and better injector education using smaller dose/session, avoiding boosters, and adhering to longer injection intervals. The current literature supports the notion that, like
BoNT-A (Botox), BoNT-B (Myobloc) also maintains its effectiveness over long-term use. 37 However, immunoresistance to BoNT-B has not been well studied and warrants investigation.
Surgical Treatment
Deep brain stimulation (DBS) of globus pallidus pars interna (GPi) has shown promise in small prospective studies. A recent Canadian multicenter, doubleblind study of 10 patients demonstrated 43% improvement of dystonia severity score and 59% improvement of TWSTRS total score compared with the pre-treatment values. 38 A previous single-center study of 10 patients with refractory CD with long-term follow up (31±21 months) also reported 55% improvement of dystonia severity score after DBS. 39 These reports are encouraging, since the results are higher than the 20-30% improvement reported for selective rizotomy with myotomy. 40, 41 Furthermore, DBS may have less permanent side effects than rhizotomy, and patients with rizotomy may require repeat operations for re-innervation of the target muscles.
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Cervical Anatomy and Injection Technique
The human neck contains many muscles, but only a handful are actively involved in CD. The easy surface accessibility of these muscles for injection accounts for the high rate of successful BoNT therapy of CD. Table 1 
